Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established....
Saved in:
Sonstige: | |
---|---|
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (206 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
LEADER | 04224nam-a2201069z--4500 | ||
---|---|---|---|
001 | 993562964604498 | ||
005 | 20231214133656.0 | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 202210s2022 xx |||||o ||| 0|eng d | ||
020 | |a 3-0365-5222-7 | ||
035 | |a (CKB)5670000000391619 | ||
035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/93214 | ||
035 | |a (EXLCZ)995670000000391619 | ||
041 | 0 | |a eng | |
100 | 1 | |a Allison, Simon J |4 edt | |
245 | 1 | 0 | |a Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
246 | |a Novel Anti-cancer Agents and Cellular Targets and Their Mechanism | ||
260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
300 | |a 1 electronic resource (206 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
520 | |a Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges. | ||
546 | |a English | ||
650 | 7 | |a Technology: general issues |2 bicssc | |
650 | 7 | |a History of engineering & technology |2 bicssc | |
653 | |a microtubule acetylation | ||
653 | |a triple-negative breast cancer | ||
653 | |a anti-cancer agent | ||
653 | |a apoptosis | ||
653 | |a K562 | ||
653 | |a 8-hydroxydaidzein | ||
653 | |a autophagy | ||
653 | |a BCR-ABL | ||
653 | |a MAPK | ||
653 | |a NF-κB | ||
653 | |a c-myc | ||
653 | |a RNA interference | ||
653 | |a siRNA | ||
653 | |a oncogene | ||
653 | |a gene silencing | ||
653 | |a expression | ||
653 | |a nanosystems | ||
653 | |a Cytochrome P450 | ||
653 | |a CYP1A1 | ||
653 | |a CYP1B1 | ||
653 | |a CYP2W1 | ||
653 | |a breast cancer | ||
653 | |a prodrug | ||
653 | |a bioprecursor | ||
653 | |a duocarmycin | ||
653 | |a phortress | ||
653 | |a AQ4N | ||
653 | |a 5-FU resistance | ||
653 | |a colorectal cancer | ||
653 | |a drug repurposing | ||
653 | |a Genomics of Drug Sensitivity in Cancer | ||
653 | |a Connectivity Map | ||
653 | |a anticancer drug | ||
653 | |a B-lactam steroid alkylators | ||
653 | |a synthetic lethality | ||
653 | |a poly (ADP-ribose) polymerase inhibitors | ||
653 | |a ovarian cancer | ||
653 | |a hybrid steroidal alkylating agents | ||
653 | |a migration | ||
653 | |a invasion | ||
653 | |a glioblastoma | ||
653 | |a CCN1 | ||
653 | |a mesenchymal-amoeboid transition | ||
653 | |a biomarker | ||
653 | |a HepG2 | ||
653 | |a Huh7 | ||
653 | |a isatin sulfonamides | ||
653 | |a angiogenesis | ||
653 | |a cancer hallmarks | ||
653 | |a molecular docking | ||
653 | |a EGFR tyrosine kinase inhibitor | ||
653 | |a photon upconversion | ||
653 | |a triplet-triplet annihilation | ||
653 | |a in vivo imaging | ||
653 | |a PLGA | ||
653 | |a nanoparticles | ||
653 | |a affibody molecule | ||
653 | |a human epidermal growth factor receptor 3 (HER3) | ||
653 | |a BxPC-3 | ||
653 | |a emtansine | ||
653 | |a DM1 | ||
653 | |a albumin binding domain | ||
653 | |a affibody drug conjugate (AffiDC) | ||
776 | |z 3-0365-5221-9 | ||
700 | 1 | |a Allison, Simon J |4 oth | |
906 | |a BOOK | ||
ADM | |b 2023-12-15 06:02:20 Europe/Vienna |f system |c marc21 |a 2022-11-05 21:33:14 Europe/Vienna |g false | ||
AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5340568990004498&Force_direct=true |Z 5340568990004498 |b Available |8 5340568990004498 |